Phase 2 Stomach Cancer Trial, Recruiting NCT05977998 Sponsor: M.D. Anderson Cancer Center Condition: Stomach Cancer
Back to Stomach Cancer

Phase 2 Stomach Cancer Trial, Recruiting

NCT05977998
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 or older (there is no upper age limit)
  • People whose general health and ability to carry out daily activities meets a certain minimum level, based on standard medical scoring scales (confirm with trial site)
  • People who have been diagnosed with a type of cancer called adenocarcinoma, located in the stomach or where the stomach meets the oesophagus, confirmed by laboratory testing of cells or tissue
  • People whose kidneys and blood cell counts are within acceptable ranges, including white blood cell count, infection-fighting cells (neutrophils), platelets, and a measure of kidney function (confirm with trial site for specific values)
  • People whose cancer has spread to the lining of the abdomen (the peritoneum), confirmed either by fluid testing or by a surgical examination procedure
  • People who have already completed a course of chemotherapy given before surgery (certain other treatments such as HER2-targeted therapy or immunotherapy may have continued alongside this)
  • Both English-speaking and non-English-speaking people are eligible

Who may not be able to join:

  • People whose cancer has spread beyond the abdominal lining to other organs, such as the liver, brain, or lungs
  • People who have an active infection, such as pneumonia or a wound infection, that would interfere with treatment
  • Women who are pregnant (a pregnancy test will be required); women who could become pregnant must agree to use reliable contraception and not breastfeed; men who could father a child must agree to use appropriate contraception or abstinence
  • People with unstable chest pain (angina) or moderate-to-severe heart failure
  • People who, for reasons such as cognitive difficulties, may not be able to follow the study procedures and appointments
  • People who have previously had a severe or life-threatening allergic reaction to the chemotherapy used in this study
  • People who have had previous surgery that would make it unsafe to perform the surgical procedures involved in this trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Brian Badgwell, MD, M.D. Anderson Cancer Center

Phone: 713-535-0703

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
8 September 2023
Est. completion
31 October 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov